Mercer Capital Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Mercer Capital Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,600	Closed	-$74K	–	278
2016 Q3	$74K	Hold	1,600	–	–	0.06%	142
2016 Q2	$80K	Hold	1,600	–	–	0.07%	131
2016 Q1	$86K	Hold	1,600	–	–	0.07%	117
2015 Q4	$105K	Hold	1,600	–	–	0.09%	111
2015 Q3	$90K	Hold	1,600	–	–	0.08%	114
2015 Q2	$95K	Hold	1,600	–	–	0.09%	121
2015 Q1	$100K	Hold	1,600	–	–	0.09%	119
2014 Q4	$92K	Buy	+1,600	New	+$89.1K	0.08%	121

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Mercer Capital Advisers's TEVA Position: Q4 2016 in Review

Mercer Capital Advisers sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 1,600 shares — an estimated $74K sold.

Mercer Capital Advisers first reported a position in TEVA in Q4 2014 and held it in 8 quarters. The position peaked at $105K in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Mercer Capital Advisers reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Mercer Capital Advisers sold 1,600 Teva Pharmaceuticals shares in Q4 2016, an estimated $74K.
Mercer Capital Advisers first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Mercer Capital Advisers's Teva Pharmaceuticals position peaked at $105K in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Mercer Capital Advisers's 13F filing for Q4 2016, filed 20 Jan 2017.